HDL cholesterol efflux capacity and cardiovascular events [3]

New England Journal of Medicine

Volumn 372, Issue 19, 2015, Pages 1870-1871

  Ritsch, Andreas ^a   Scharnagl, Hubert ^b   März, Winfried ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL TRANSPORT; HIGH RISK PATIENT; HUMAN; LETTER; MACROPHAGE; MORTALITY; PRIORITY JOURNAL; FEMALE; MALE; METABOLISM;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE;

EID: 84928978981     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1503139     Document Type: Letter

References (3)

1. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
2. Ritsch A, Scharnagl H, Eller P, et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010;121:366-74.
3. Scharnagl H, Heuschneider C, Sailer S, Kleber ME, März W, Ritsch A. Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels. Eur J Clin Invest 2014;44:395-401.